AT101 is a small molecule inhibitor of protein arginine methyltransferase 5 (PRMT5), developed through IngenOx’s in-house drug discovery programme. The compound works by inhibiting PRMT5’s ability to symmetrically di-methylate arginine residues, a process critical to tumour growth and progression. Currently undergoing IND-enabling studies, AT101 is paired with a companion diagnostic to identify patients most likely to benefit from treatment. The asset is set to enter a Phase I study focused on evaluating the safety and dosage of AT101. Preclinical studies have identified biomarkers strongly correlated with PRMT5-driven tumour responses, and early data suggests that AT101 may offer a differentiated profile compared to competitor compounds, potentially leading to a favourable risk-benefit ratio in the clinic.
JASON Study on Immunologically Cold Cancers
This is a study that will investigate the safety and dosage of AT101. We have identified a group of biomarkers that correlate strongly with PRMT5-driven tumor response. AT101 also shows a differentiated profile when compared to competitor compounds, which could translate to a different risk-benefit ratio in the clinic.